Next 10 |
home / stock / redif / redif news
RedHill Biopharma Ltd. (RDHL) Q3 2021 Earnings Conference Call Nov 30, 2021 08:30 AM ET Company Participants Alexandra Okmian - Senior Business Development and IR Manager Dror Ben-Asher - CEO Guy Goldberg - Chief Business Officer Gilead Raday - COO Rob Jackson - SVP, Sales and Marketing Micha...
The following slide deck was published by RedHill Biopharma Ltd. in conjunction with their 2021 Q3 earnings call. For further details see: RedHill Biopharma Ltd. 2021 Q3 - Results - Earnings Call Presentation
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results Canada NewsWire RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation...
RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Nov. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty b...
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Canada NewsWire - Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107...
RedHill Biopharma Presents New Talicia® and Movantik® Data Analyses at ACG 2021 Two new analyses evaluate pharmacological and clinical advantages of Talicia® as first-line H. pylori therapy over clarithromycin-based regimens Two new analyses of Movantik® ...
RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034 - The patent is directed to the Talicia® formulation and pharmaceutical kits for use in the treatment of H. pylori infection - The new patent, valid through 2034, will be t...
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo The settlement agreement with Aurobindo brings closure to all presently pending Movantik® patent litigation brought pursuant to The Drug Price Competition and Patent Term Restoration A...
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval PR Newswire The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-...
RedHill Biopharma Ltd. (RDHL) Q2 2021 Earnings Conference Call August 26, 2021 8:30 AM ET Company Participants Alexandra Okmian - Senior Business Development and Investor Relations Manager Dror Ben-Asher - Chief Executive Officer Guy Goldberg - Chief Business Officer Gilead Raday - Chief Oper...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd Ord Company Name:
REDIF Stock Symbol:
OTCMKTS Market:
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results Canada NewsWire RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation...
RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Nov. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty b...
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Canada NewsWire - Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107...